Ischemia-modified albumin: a novel blood marker of endoscopic mucosal healing in inflammatory bowel disease
- Author:
Seung Bum LEE
1
;
Hyun-Ki KIM
;
Sang Hyuk PARK
;
Ji-Hun LIM
;
Sang Hyoung PARK
Author Information
- Publication Type:Original Article
- From:Intestinal Research 2024;22(1):75-81
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background/Aims:The achievement of endoscopic remission is an important therapeutic goal in the treatment of inflammatory bowel diseases (IBD). We aimed to evaluate the role of fecal calprotectin (FCP) and ischemia-modified albumin (IMA) as biomarkers for evaluating IBD disease activity.
Methods:A total of 48 patients with IBD (20 with ulcerative colitis and 28 with Crohn’s disease) were included in this study. FCP and serum C-reactive protein levels, erythrocyte sedimentation rate, and IMA were measured in patients with IBD and compared with endoscopic findings.
Results:Elevated FCP and serum IMA levels were significantly associated with endoscopic non-mucosal healing. The correlation between FCP and IMA was not significant. Analysis of the receiver operating characteristic curve showed that both FCP and IMA had diagnostic value in predicting non-mucosal healing. When the Ln(FCP)+IMA/10 value was calculated using both factors, the predictive value for non-mucosal healing increased; however, no significant difference was observed.
Conclusions:IMA could be a candidate serum biomarker for predicting endoscopic mucosal healing in IBD.
